Skip to main content

Patrick M. Reagan, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5823

Fax: (585) 784-7097

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Setting



I am a clinician and researcher specializing in the care of patients with both Non Hodgkin and Hodgkin lymphomas. Areas of particular interest include aggressive B-cell lymphomas, autologous stem cell transplantation and cellular therapy including chimeric antigen receptor (CAR) T-cells.

Lymphomas are a complex group of diseases and require a multidisciplinary team to manage. We are fortunate to have an excellent team at the Wilmot Cancer Institute including hematology and oncology, radiation oncology, hematopathology, dermatology, neurology, nursing, advanced practice providers, social work and members of the clinical trials office.

I am actively engaged in clinical trials research and feel that this is an important component of care for lymphoma patients.

Professional Background

Dr. Reagan is an Associate Professor of Medicine at the Wilmot Cancer Institute.

Dr. Reagan received his medical degree from Upstate Medical University in Syracuse, NY. He completed his internship and residency at the University of Virginia. He then served as a chief resident at the University of Virginia. He completed his fellowship in hematology at the Wilmot Cancer Institute at the University of Rochester Medical Center.

He started his faculty appointment at the Wilmot Cancer Institute in July 2015.




    MD | SUNY Upstate College of Health Professions

    Post-doctoral Training & Residency

    07/01/2013 - 06/30/2015
    Fellowship in Hematology & Oncology at University of Rochester Medical Center

    07/01/2012 - 07/01/2013
    Residency in Internal Medicine at University of Virginia-Radiology GME

    07/01/2010 - 07/01/2012
    Residency in Internal Medicine at University of Virginia-Radiology GME

    07/01/2009 - 07/01/2010
    Internship in Internal Medicine at University of Virginia-Radiology GME

    VIEW ALL expand_more


    Wilmot Cancer Institute Inspiration Award Immune Effector Cell Therapy Team

    Lymphoma Research Foundation Clinical Research Mentoring Program

    American Society of Hematology Clinical Research Training Institute

    John and Carol Bennett Travel Fellowship Award
    Sponsor: John and Carol Bennett
    Location: Wilmot Cancer Institute

    Alpha Omega Alpha, Upstate Medical University
    Sponsor: Upstate Medical University

    Phi Beta Kappa, St. Lawrence University
    Sponsor: St. Lawrence University

    Academic All American, Football, St. Lawrence University
    Sponsor: St. Lawrence University

    Beta Beta Beta, Biological Honor Society, St. Lawrence University
    Sponsor: St. Lawrence University

    VIEW ALL expand_more


    Journal Articles

    Ghobadi A, Munoz J, Westin JR, Locke FL, Miklos DB, Rapoport AP, Perales MA, Reagan PM, McGuirk JP, Jacobson CA, Kersten MJ, Avivi I, Peng A, Schupp M, To C, Oluwole OO. "Outcomes of subsequent anti-lymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7." Blood advances.. 2024 Feb 5; Epub 2024 Feb 05.

    Jain MD, Jacobs MT, Gao F, Nastoupil LJ, Spiegel JY, Lin Y, Dahiya S, Lunning MA, Lekakis LJ, Reagan PM, Oluwole OO, McGuirk JP, Deol A, Sehgal A, Goy A, Hill BT, Andreadis C, Munoz J, Chavez JC, Bennani NN, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Ghobadi A. "Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: Results from the US lymphoma CAR-T consortium." Blood advances.. 2023 Nov 16; Epub 2023 Nov 16.

    Roschewski M, Patel MR, Reagan PM, Saba NS, Collins GP, Arkenau HT, de Vos S, Nuttall B, Acar M, Burke K, White RD, Udriste M, Sharma S, Dougherty B, Stetson D, Jenkins D, Mortlock A, Forcina A, Munugalavadla V, Flinn I. "Phase 1 Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2023 Jun 26; Epub 2023 Jun 26.



    At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information.